List volumes - List articles in this issue

Short communication

First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus

doi: 10.2340/00015555-1746


Abstract is missing (Short)


Yung-Tsu Cho, Fang-Yu Lee, Chia-Yu Chu, Li-Fang Wang
Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, 15 F, No.7, Chung-Shan S. Rd., Taipei 10002, Taiwan


1. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772–1779.

2. Joly P, Mouquet H, Roujeau JC, D’lncan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545–552.

3. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42: 422–427.

4. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043–1046.

5. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622–628.

6. Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shphilberg O, Raanani P. Rituximab-associated acute thrombocytopenia: An under-diagnosed phenomenon. Am J Hematol 2009; 84: 247–250.

7. Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, et al. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 2011; 90: 1145–1151.

8. Schmidt E, Hunzelmann N, Zillikens D, Brocker EB, Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31: 503–508.

9. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in refractory autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352–356.

10. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011; 165: 646–651.

11. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012; 166: 405–412.

12. Matsukura S, Knowles SR, Walsh S, Shear NH. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus. Arch Dermatol 2012; 148: 734–739.

13. Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, et al. Adjuvant rituximab therapy for pemphigus: a single-center experience of 31 patients. Arch Dermatol 2012; 148: 1031–1036.

Related articles

There are no related articles.

Share with your friends



Full text



There is no supplementary for this article.

Print information

Volume 94, Issue 4

DOI: 10.2340/00015555-1746

Pages: 472-473

View at PubMed